About OneCell Diagnostics
OneCell Diagnostics is a company based in Cupertino (United States) founded in 2021 by Mohan Uttarwar and Aravindan Vasudevan. It operates as a B2B and SaaS. OneCell Diagnostics has raised $16 million across 1 funding round from investors including Cedars Sinai, Tenacity Ventures and Celesta. The company has 33 employees as of March 31, 2023. OneCell Diagnostics offers products and services including OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and iCare. OneCell Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter Cupertino, United States
- Employees 33 as on 31 Mar, 2023
- Founders Mohan Uttarwar, Aravindan Vasudevan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Onecell Diagnostics India Private Limited
- Date of Incorporation 20 Dec, 2021
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$1.38 M (USD)624.26as on Mar 31, 2023
-
Net Profit
$5.36 K (USD)1.35as on Mar 31, 2023
-
EBITDA
-$1.19 M (USD)-50341.75as on Mar 31, 2023
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series A
Nov 20, 2024
-
Investors
Cedars Sinai
& 4 more
-
Employee Count
33
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OneCell Diagnostics
OneCell Diagnostics offers a comprehensive portfolio of products and services, including OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and iCare.
Comprehensive genomic profiling for detecting cancer alterations and insights.
Detects circulating tumor cells to assess cancer metastasis risks.
Monitors cancer progression through blood-based disease tracking.
Evaluates hereditary cancer risks via gene panel analysis.
AI application for personalized cancer treatment and monitoring.
Tool for analyzing research data in oncology studies.
People of OneCell Diagnostics
Unlock access to complete
Funding Insights of OneCell Diagnostics
OneCell Diagnostics has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series A round of $16 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OneCell Diagnostics
OneCell Diagnostics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Cedars Sinai, Tenacity Ventures and Celesta.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Technology investment firm focusing on early-growth stages and software businesses in India.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for OneCell Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OneCell Diagnostics
Investment portfolio details for OneCell Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OneCell Diagnostics
Detailed financials for OneCell Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Onecell Diagnostics Comparisons
Peer comparison for OneCell Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OneCell Diagnostics
OneCell Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of OneCell Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Onecell Diagnostics
Complete news archive for OneCell Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OneCell Diagnostics
OneCell Diagnostics was founded in 2021 and raised its 1st funding round 3 years after it was founded.
OneCell Diagnostics is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
Mohan Uttarwar is the current CEO of OneCell Diagnostics. They have also founded this company.
OneCell Diagnostics is a funded company, having raised a total of $16M across 1 funding round to date.
As of Mar 31, 2023, the latest employee count at OneCell Diagnostics is 33.
Annual revenue of OneCell Diagnostics is $1.38M as on Mar 31, 2023.
OneCell Diagnostics focuses on precision oncology by developing advanced genomic and AI-based tests for cancer detection and management. They provide services like blood tests for circulating tumor cells and longitudinal monitoring tools. Operating from offices in the United States and India, they serve healthcare providers, patients, and researchers with data analytics platforms to improve treatment decisions and outcomes.
OneCell Diagnostics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
OneCell Diagnostics offers OncoIndx, OncoDiscover, OncoMonitor, OncoRisk, and 2 more products and services.
OneCell Diagnostics has 5 investors. Key investors include Cedars Sinai, Tenacity Ventures, Celesta, Eragon, and Singularity Venture Partners.